The round was led by Cormorant Asset Management and joined by the Capital Partnership, Lilly Asia Ventures and other existing shareholders, the Campbell, Calif.-based company said.
“We are pleased to expand our relationship with NuVera Medical and Shifamed. We are confident in the NuVera team’s ability to execute and deliver this important procedural advancement to the cardiology market,” Cormorant Asset Management CEO Bihua Chen said in a press release.
NuVera Medical is developing a platform that provides side-by-side 2D and 4D intracardiac images with a single ICE catheter, the company said.
“The results of our preclinical work to date have been very positive. With these results, we believe that the value proposition of the NuVera technology in electrophysiology and structural heart applications is further demonstrated, and we look forward to advancing the product to the next stage of development,” CEO Todor Jeliaskov said in a prepared statement.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.